Launca Medical Secures Tens of Millions in Extended Series B Funding to Accelerate Digital Dentistry

VCBeat (WeChat ID: vcbeat) recently learned that Guangdong Launca Medical Device Technology Co., Ltd. (hereinafter referred to as “Launca Medical”) announced the completion of a tens-of-millions-yuan follow-on financing in its Series B round, with the investor beingShenzhen Investment Holdings Donghai SME and Micro Venture Capital Enterprise (Limited Partnership), Shana Capital served as the financial advisor for this round of transaction. Previously, in January this year, Launca Medical secured tens of millions of yuan in Series B financing, led by Guozhong Venture Capital.

Launca Medical, established in October 2013, is a national high-tech enterprise integrating research and development, production, and sales. The company specializes in the independent innovation, industrialization, and marketing of digital dental equipment and materials, such as intraoral scanners. It is committed to providing global dental markets with a "one-stop" dental diagnosis and treatment service and digital solutions, ranging from intraoral scanning to denture fabrication. Currently, Launca has stationed training and commercial personnel in 18 provinces and municipalities across China, with its products exported to more than 50 countries and regions worldwide.

Mr. Lv Jian, Founder and CEO of Launca Medical, earned his bachelor’s degree from Tsinghua University and his Ph.D. from the California Institute of Technology. With nearly two decades of experience in technical research and commercialization within the fields of 3D imaging and dental industrialization, he possesses a profound understanding of the dental market.

China's dental market is growing rapidly, but the current number of domestic dentists cannot meet market demand.。

According to the report "China's Oral Care Industry from a Global Perspective" released by VBInsight in June 2019, China's oral care industry is growing rapidly at a rate 50%–100% higher than GDP growth. However, there are only 100 dentists per million people in China, a significant gap compared with the 500–2,000 dentists per million seen in developed or moderately developed countries in Europe and America. The national development goal is to achieve one dentist for every 4,000–5,000 people by 2030. This means that over the next 10–20 years, the number of dental hospitals and clinics in China will need to expand fivefold compared with current levels. It is this industrial landscape that has spurred the emergence of a faster, more convenient, and intelligent digital oral care industry.

Acquiring accurate intraoral impression data is the foundation for realizing digital diagnosis and treatment.。

Prior to 2015, the domestic market offered only a handful of imported intraoral scanners, which were prohibitively expensive and saw limited clinical adoption. Addressing these industry pain points, Launca Medical dedicated two years to intensive research and development, launching its first digital intraoral scanner, the DL-100, in 2015. Built on proprietary 3D scanning technology, the DL-100 secured 26 intellectual property rights and broke the international technological monopoly.

In November 2019, Launca Medical launchedThe New Generation Intraoral Scanner—DL-200。

Dr. Lv Jian introduced that the DL-200 series intraoral scanners, built on advanced algorithms and imaging technologies, have undergone comprehensive upgrades. While retaining the technical advantages of the DL-100, such as its precision metrics, the new series introduces innovative features including powder-free scanning, true-color video scanning, micron-level accurate modeling, a large depth-of-field view, and detachable scanning tips.

The DL-200 Series Intraoral Scanner is widely used in surgical guide fabrication, aesthetic restoration, and clear aligner orthodontics, enabling dentists to perform clinical procedures more efficiently and conveniently. Highly favored by dental practitioners and dental laboratories worldwide, the product has successfully obtained CE and FDA certifications.

Upon the completion of this round of financing, Launca Medical will further leverage industrial implementation resources and collaborate with upstream and downstream partners to accelerate the research and development of technologies and solutions in the field of dental digitalization. The company aims to establish a more comprehensive closed-loop service covering the entire digital workflow, extending its reach from hardware and software infrastructure in dental digitalization to consumer-end product solutions, ultimately achieving integration across the entire industry chain ecosystem.

At the same time, the company will base itself in China, accelerate its international market layout, increase the proportion of R&D and operations in North America and Europe, continuously expand its business areas, improve its layout across China and globally, and bring more value to users, clinics, hospitals, and shareholders.

Toukong Donghai Investment TeamIt was stated that the oral care industry is currently at a critical juncture in its digital transformation. As one of the first domestic enterprises to venture into the digital dentistry sector, Guangdong Launca Medical Device Technology Co., Ltd. (Launca Medical) has already achieved remarkable performance and breakthroughs in digital products. The company holds dozens of digital patents and has collaborated with upstream and downstream partners to establish a comprehensive, closed-loop industrial chain for digital prosthodontics, implantology, and orthodontic restoration. Supported by robust R&D and training teams, Launca Medical has built unique competitive barriers in China’s dental sector, demonstrating high growth potential and significant development prospects. Toukong Donghai is optimistic about Launca Medical’s strategic layout in digital dentistry and is confident in helping the company continuously expand its boundaries, empower the industry through digitalization, and solidify its long-term position as a leading enterprise in digital dentistry.

Toukong Donghai, established on January 8, 2015, is a market-oriented technology equity investment and asset management platform that leverages the combined strengths of its founders. It was initiated by Shenzhen Investment Holdings (SIHC), in partnership with Haier Technology and China Venture Capital East. Leveraging robust shareholder resources, the company specializes in industrial investment, actively plays the pioneering role of state-owned capital, and builds a comprehensive innovation and entrepreneurship investment ecosystem featuring synergistic collaboration among funds, industrial parks, industries, and scientific and technological institutions. Toukong Donghai was successfully selected for the CVSource 2017 Top 50 Best Early-Stage Venture Capital Firms in China, the CVSource 2018 Top 30 Best Early-Stage Venture Capital Firms in China, and the CVSource 2019 Top 30 Best Early-Stage Venture Capital Firms in China.